PAHO / WHO: Although new vaccines are more costly than traditional ones, they are overwhelmingly cost-effective and should continue to be considered a public health "best buy." See more here.
This resource collaborative is housed at the Harvard T.H. Chan School of Public Health, Center for Health Decision Sciences and Department of Global Health and Population. This work is made possible with funding from the Bill & Melinda Gates Foundation.